Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenformin, Methylene Blue, PDT, Zinc and Potassium for Severe COVID-19
NCT05003492Phase 2Unknown
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of phenformin and methylene blue in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Lung Injury Score at 14 days. Status: unknown.
02
Drugs
phenforminmethylene blue
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05003492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003492.